The long wait for targeted systemic therapies to manage desmoid tumors could be over after a second drug directed against the Notch pathway has shown promise.
SAN DIEGO, Sept. 07, 2022 Biora Therapeutics, Inc. , the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical. | September 7, 2022
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results Successfully completed PM-602 human study for its targeted. | August 15, 2022